Scott Olson/Getty Images News
German conglomerate Bayer (OTCPK:BAYZF) marked a trial win in Arkansas on Friday in a case alleging that the company’s Roundup weedkiller caused cancer, while a similar trial in Delaware ended without a verdict.
In the Arkansas case, the plaintiffs alleged that Roundup, which Bayer (OTCPK:BAYRY) acquired as part of its $63B buyout of U.S. agrochemical company Monsanto in 2018, caused a cancer called non-Hodgkins lymphoma in an Arkansas woman.
After the verdict in the trial at Arkansas State Court came, Bayer (OTCPK:BAYZF) said the decision marked the company’s 11th legal victory in the last 17 Roundup cases.
The verdict “validates the company’s strategy of taking cases to trial based on strong scientific and regulatory evidence,” the company said, according to Bloomberg.
Earlier in the day, a Delaware Superior Court judge declared a mistrial in a separate Roundup lawsuit filed by the family of Anthony Cloud, a South Carolina groundskeeper who died in 2021.
After more than three days of deliberations, jurors in state court in Wilmington failed to reach an agreement on whether exposure to Roundup caused Cloud’s non-Hodgkins lymphoma.
With more than 50,000 claims pending, plaintiffs in some Roundup cases have secured significant verdicts against Bayer (OTCPK:BAYRY) in recent months, including a $2.25B payout from a single lawsuit in a Philadelphia court in January.